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Abstract
Alzheimer’s disease (AD), and its precursor state, mild cognitive impairment
(MCI), continue to be widely studied. While there is no consensus on whether
MCIs actually “convert” to AD, this concept is widely applied, allowing sta-
tistical testing and machine learning methods to help identify early disease
biomarkers and build models for predicting disease progression. Thus, the
more important question is not whether MCIs convert, but what is the best
such definition. We focus on automatic prognostication, nominally using only
a baseline image brain scan, of whether an MCI individual will convert to AD
within a multi-year period following the initial clinical visit. This is in fact
not a traditional supervised learning problem since, in ADNI, there are no
definitive labeled examples of MCI conversion. It is not truly unsupervised,
either, since there are (labeled) AD and Control subjects, as well as clini-
cal and cognitive scores for MCIs. Prior works have defined MCI subclasses
IData used in preparation of this article were obtained from the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the in-
vestigators within the ADNI contributed to the design and implementation of ADNI
and/or provided data but did not participate in analysis or writing of this report. A
complete listing of ADNI investigators can be found at: http://adni.loni.ucla.edu/wp-
content/uploads/how to apply/ADNI Authorship List.pdf
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based on whether or not clinical/cognitive scores significantly change from
baseline. There are serious concerns with these definitions, however, since
e.g. most MCIs (and ADs) do not change from a baseline CDR=0.5 at any
subsequent visit in ADNI, even while physiological changes may be occur-
ring. These works ignore rich phenotypical information in an MCI patient’s
brain scan and labeled AD and Control examples, in defining conversion.
We propose an innovative conversion definition, wherein an MCI patient is
declared to be a converter if any of the patient’s brain scans (at follow-up
visits) are classified “AD” by an (accurately-designed) Control-AD classifier.
This novel definition bootstraps the design of a second classifier, specifically
trained to predict whether or not MCIs will convert. This second classifier
thus predicts whether an AD-Control classifier will predict that a patient
has AD. Our results demonstrate this new definition leads not only to much
higher prognostic accuracy than by-CDR conversion, but also to subpopu-
lations much more consistent with known AD brain region biomarkers. We
also identify key prognostic region biomarkers, essential for accurately dis-
criminating the converter and nonconverter groups.
Keywords: Alzheimer’s, mild cognitive impairment, AD conversion, MRI,
support vector machines, feature selection, AD biomarkers, MFE, RFE
1. Introduction
The dementing illness Alzheimer’s disease (AD), and the transitional
state between normal aging and AD referred to as mild cognitive impair-
ment (MCI) continue to be widely studied. Individuals diagnosed with MCI
have memory impairment, yet without meeting dementia criteria. Annually
≈ 10-15% of people with MCI are diagnosed with AD (Petersen, 2004). More-
over, prior to symptom onset, brain abnormalities have been found in people
with MCI, as ascertained by retroactive evaluation of longitudinal MRI scans
(Davatzikos et al., 2008). There is no consensus on whether MCI patients
actually “convert” to AD. First, some MCI patients may suffer from other
neurodegenerative disorders (e.g., Lewy body dementia, vascular dementia
and/or frontotemporal dementia). Second, it is possible that all other MCI
patients already have AD, but at a preclinical stage. AD diagnosis itself may
not be considered definitive without e.g. confirming pathologies such as the
amyloid deposits detectable at autopsy. Regardless of whether MCI patients
truly “convert” to AD or not, the concept of MCI-to-AD conversion has been
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widely applied, e.g. (Chou et al., 2009; Davatzikos et al., 2010; Misra et al.,
2009; Vemuri et al., 2009; Zhang et al., 2011) and is utilitarian – defining
MCI (converter and nonconverter) subgroups allows use of statistical group
difference tests and machine learning methods to help identify early disease
biomarkers and to build models for predicting disease progression. For these
purposes, the more important question is not whether MCIs convert, but
rather what is the best such definition.
Accordingly, here we focus on the following Aim: automatic prognos-
tication, (nominally) using only a baseline brain scan, of whether an MCI
individual will convert to AD within a multi-year (three year) period follow-
ing an initial (baseline) clinical visit1.
While only image voxel-based features are evaluated here for use by our
classifier, our framework is extensible to incorporating other baseline clinical
information (e.g. weight, gender, education level, genetic information, and
clinical cognitive scores such as the Mini Mental State Exam (MMSE)) into
the decisionmaking. Moreover, our approach can also incorporate the recent,
promising cerebrospinal fluid (CSF) based markers (De Meyer et al., 2010).
However, as this requires an invasive spinal tap, we focus here on image scans,
which are routinely performed for subjects with MCI.
We do not hypothesize that, within ADNI, there are actually two sub-
classes of MCI subjects when evaluated over the very long term – those that
(eventually) convert to AD, and those that do not. Even if an overwhelm-
ing majority of MCI subjects will eventually convert, identifying the sub-
group likely to convert within several years has several compelling utilities:
1) early prognosis, to assist family planning; 2) facilitating group-targeted
treatments/drug trials; 3) we identify key prognostic brain “biomarker” re-
gions, i.e. those found to be most critical for accurately discriminating our
“converter” and “nonconverter” groups. These regions may shed light on
disease etiology.
Distinguishing AD converters from nonconverters is a binary (two-class)
classification problem. Moreover, it may appear this classification problem
can be directly addressed via supervised learning methods (Duda et al., 2001).
However, it is in fact an unconventional problem, lying somewhere between su-
pervised classification and unsupervised classification (clustering), and thus
1Our system performs three-year ahead prediction because it is designed based on the
ADNI database, which followed participants for a period of up to three years.
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requiring a unique approach. To appreciate this, consider the ADNI cohort
of MCI individuals. ADNI consists of clinical information and image scans on
hundreds of participants, taken at six-month intervals for up to three years.
A clinical label (AD, MCI, or Control) was assigned to each participant at
first visit2. Even though a probable AD definition based on CDR and MMSE
scores and NINCDS/ADRDA criteria has been used, e.g. (Leow et al., 2009;
Zhang et al., 2011), to provide follow-up assessment for MCI patients, this is
strictly a clinically driven definition, based on a clinical rating (CDR) and a
cognitive score (MMSE) whose difficulties will be pointed out shortly. This
is not a definitive (autopsy-based) determination of AD, nor is it a definition
based on physiological brain changes. Even if the probable AD definition has
very high specificity, it may not be sufficiently sensitive, i.e. there may be pa-
tients who are undergoing significant physiological brain changes consistent
with conversion, yet without clinical manifestation.
Accordingly, we will approach the conversion problem from a perspective
as agnostic and unbiased as possible, and simply state that it is not defini-
tively known which MCI participants in ADNI truly converted to AD within
three years. In conventional supervised classifier learning, one has labeled
training examples, used for designing the classifier, and labeled test exam-
ples, used to estimate the classifier’s generalization accuracy. For predicting
whether MCI participants in ADNI convert to AD, we in fact have neither.
Thus, our problem is not conventional supervised learning. On the other
hand, consider unsupervised clustering (Duda et al., 2001). Here, even if one
knows the number of clusters (classes) present, there is no prior knowledge
on what is a good clustering – one is simply looking for underlying group-
ing tendency in the data. Clearly, our problem does not fit unsupervised
clustering, either – while we have no labeled MCI converter/nonconverter
instances per se, 1) there are two designated classes of interest (converter
and nonconverter); and 2) there are known class characteristics – conversion
to AD should, plausibly, mean that: (i) a clinical measure such as CDR or
a cognitive measure has changed and/or (ii) there are changes in brain fea-
tures more characteristic of AD subjects than normal/healthy subjects. Note
that in ADNI we do have plentiful labeled AD and normal/healthy (Control)
2Clinicians derive the AD/MCI/Control label based on multiple criteria, which may
include Clinical Dementia Rating (CDR), whose possible values are: 0=none, 0.5=ques-
tionable, 1=mild, 2=moderate, 3=severe.
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examples to help assess ii).
Based on the above, MCI prognosis is an interesting and novel problem,
lying somewhere between supervised and unsupervised classification. The
crux of this problem is to craft criteria through which meaningful MCI sub-
groups can be defined, well-capturing notions of “AD converter” and “non-
converter”. To help guide development and evaluation of candidate defini-
tions, we state the following three desiderata: 1) The proposed definition
of AD converter should be plausible and should exploit the available, rele-
vant information in the ADNI database (e.g. image data, labeled AD and
Control examples, and clinical information). To appreciate 1), note that
the MCI population could be dichotomized in many ways, e.g. by height,
and there might be significant clustering tendency with respect to height,
but such a grouping is likely meaningless for MCI prognosis; 2) A classifier
trained based on these class definitions should generalize well on test data
(not used for training the classifier) – this quantifies how accurately we can
discriminate the classes that we have defined. If we create what we believe
to be good definitions, but ones that cannot be accurately discriminated,
that would not be useful clinically; 3) The class definitions should be vali-
dated using known AD conversion biomarkers (i.e., external measures) such
as measured changes from baseline both in volumes of brain regions known
to be associated with the disease (Schuff et al., 2010) and in cognitive test
scores (such as the clinical MMSE measure).
Prior Related Work
Several prior works, e.g. (Davatzikos et al., 2010; Misra et al., 2009; Wang
et al., 2010), defined converter and nonconverter classes solely according to
whether the baseline visit CDR score of 0.5 rose or stayed the same over
all visits. Change in CDR has also been used as surrogate ground-truth for
cognitive decline in a number of other papers, e.g. (Chou et al., 2010; Vemuri
et al., 2009). While CDR gives a workable conversion definition, it should
be evaluated with respect to the three desiderata above. We will evaluate 2)
and 3) in the sequel. With respect to 1), one should challenge a CDR-based
conversion definition. First, CDR is not an effective discriminator between
the AD and MCI groups, i.e. there is very significant AD-MCI overlap,
not only with respect to CDR=1 but even 0.5 – for ADNI, the majority of
the hundreds of AD subjects used in our experiments start (at first visit)
at CDR=0.5 and stay at 0.5 at all later visits; likewise, nearly all MCI
subjects start at 0.5, with a large majority of these also staying at 0.5 for
all visits. This latter fact further implies difficulties in finding an adequate
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number of conversion-by-CDR subjects in ADNI, both for accurate classifier
training and test set evaluation. For the even more stringent probable AD
definition (meeting MMSE and NINCDS/ADRDA criteria, in addition to
CDR changing from 0.5 to 1) there are necessarily even fewer MCI converters
for classifier training and testing. Second, a purely CDR-based (or “probable
AD” based) conversion definition ignores the (rich) phenotypical information
in an MCI subject’s image brain scans and does not exploit the labeled
AD and normal/healthy (Control) examples in ADNI. These prior works do
treat features derived from brain scans as the covariates (the inputs) to the
classifier/predictor. However, we believe the MCI brain scans can themselves
be used, in conjunction with the labeled AD and Control examples, to help
define more accurate surrogate ground-truth.
Previous work has demonstrated that structural MRI analysis is useful
for identifying AD biomarkers in individual brain regions (Chetelat et al.,
2002; Fan et al., 2008; Fennema-Notestine et al., 2009) – e.g., cortical thin-
ning (Lerch et al., 2005; Thompson et al., 2003), ventricle dilation and gaping
(Chou et al., 2010, 2009; Schott et al., 2005), volumetric and shape changes
in the hippocampus and entorhinal cortex (Csernansky et al., 2005; de Leon
et al., 2006; Stoub et al., 2005), and temporal lobe shrinkage (Rusinek et
al., 2004). It is important to capture interaction effects across multiple brain
regions. (Davatzikos et al., 2008; Misra et al., 2009; Vemuri et al., 2008;
Wang et al., 2010) did jointly analyze voxels (or regions) spanning the entire
brain and did build classifiers or predictors. Moreover, as part of their work,
(Wang et al., 2010) investigated prediction of future decline in MCI subjects
working from baseline MRI scans, which is the primary subject of our cur-
rent paper. However, there are several limitations of these past works. First,
all these studies used the previously discussed CDR and cognitive measures
such as MMSE, which has been described as noisy and unreliable, as the
ground-truth prediction targets for classifier/regressor training. In (Chou et
al., 2010), the authors state: “Cognitive assessments are notoriously variable
over time, and there is increasing evidence that neuroimaging may provide
accurate, reproducible measures of brain atrophy.” Even in (Wang et al.,
2010), where MMSE was treated as the measure of decline and the ground-
truth regression target, the authors acknowledged that “individual cognitive
evaluations are known to be extremely unstable and depend on a number
of factors unrelated to...brain pathology.” Such factors include sleep depri-
vation, depression, other medical conditions, and medications. Even though
MMSE is widely used by clinicians, these comments (even if not universally
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accepted), do indicate MMSE by itself may not be so reliable in quantifying
the disease state. Moreover, while (Wang et al., 2010) did build predictors of
future MMSE scores working from baseline scans, this was not a main focus
of their paper – their paper focused on predicting the current score. Their
prognostic experiments involved a very small sample size (just 26 participants
from the ADNI database). Accordingly, it is difficult to draw definitive con-
clusions about the accuracy of their prognostic model and their associated
brain biomarkers. The main reason the authors chose such a small sample
was, as the authors state: “A large part of...ADNI...are from patients who
did not display significant cognitive decline...[these] would overwhelm the re-
gression algorithm if..used in the...experiment.” While this statement (with
cognitive decline measured according to MMSE) may be true, that does not
mean many of those excluded ADNI subjects are not experiencing significant
physiological brain changes/atrophy. The novel approach we next sketch is
well-suited to identifying MCI subjects undergoing such changes.
Our Neuroimaging-Driven, Trajectory-Based Approach
Here, we propose a novel approach for prognosticating putative conver-
sion to AD driven by image-based information (and exploiting AD-Control
examples), rather than by a single, non-image-based, weakly discriminat-
ing clinical measurement such as CDR. Our solution strategy is as follows.
We first build an accurate image-based Control-AD classifier (i.e., using AD
and Control subjects, we build a Support Vector Machine (SVM) classifier)
(Vapnik, 1998). We then apply this classifier to a training population of
MCI subjects – separately, for each subject visit, we determine whether the
subject’s image is on the AD side or the Control side of the SVM’s fixed
(hyperplane) decision boundary. In addition to a binary decision, the SVM
gives a “score” – essentially the distance to the classifier’s decision boundary.
Thus, for each MCI subject, as a function of visits, we get an image-based
“phenotypical” score trajectory. We fit a line to each subject’s trajectory
and extend the line to the sixth visit if the sixth visit is missing. We can
then give the following trajectory-based conversion definition: if the extended
line either starts on the AD side or crosses to the AD side over the six visits,
we declare this person a “converter-by-trajectory”. Otherwise, this person
is a “nonconverter-by-trajectory”3. In this fashion, we derive ground-truth
3A very small percentage of the MCI population, in our experiments often 1% and not
exceeding 5%, may unexpectedly start on the AD side and cross to the Control side. We
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“converter” and “nonconverter” labels for an (initially unlabeled) training
MCI population. These (now) labeled training samples bootstrap the de-
sign of a second SVM classifier which uses only the first-visit training set
MCI images and is trained to predict whether or not an MCI patient is a
“converter-by-trajectory”. Essentially, this second (prognostic) classifier is
predicting whether, within three years, an AD-Control classifier will predict
that a patient has AD. Via these two classifier design steps, we thus build a
classification system for our (unconventional) pattern recognition task.
SVMs are widely used classifiers whose accuracy is attributed to their
maximization of the “margin”, i.e. the smallest distance from any training
point to the classification boundary. Since the SVM finds a linear discrimi-
nant function that maximizes margin, a significant change in score is generally
needed to cross from the control side to the AD side, which is thus suggestive
of conversion from MCI to AD. This is the premise underlying our approach.
The main contributions of our work are: 1) a novel image-based prognos-
ticator of MCI-to-AD conversion that we will demonstrate to achieve both
better generalization accuracy and much higher correlation with known brain
region biomarkers than the CDR-based approach; 2) The finding that MCI
subgroups that are strongly correlated with known AD brain region biomark-
ers are not so strongly correlated with “cognitive decline” as measured by
MMSE; 3) Identification of the brain regions most critical for accurately
discriminating between our “converter” and “nonconverter” groups, via ap-
plication of margin-based feature selection (MFE) (Aksu et al., 2010) to brain
image classification, and demonstration of MFE’s better performance than
the well-known RFE method (Guyon et al., 2002) on this domain.
treat these individuals as outliers and omit them from our experiments.
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2. Methods
2.1. Subjects and MRI data
We used T1-weighted ADNI images
4 that have undergone image correc-
tion described at the ADNI website.5 ADNI aims to recruit and follow 800
research participants in the 55-90 age range: approximately 200 elderly Con-
trols, 400 people with MCI, and 200 people with AD. The number of Control,
MCI, and AD participants in our analysis were ≈180, 300, and 120, respec-
tively – experiment-specific detailed descriptions will be provided in Sec. 3.
We processed the T1-weighted images as described in Appendix A, produc-
ing new images from which we then obtained the features (next discussed)
used by our statistical classifiers.
2.2. Features for classification
We chose as features the voxel intensities of a processed6 RAVENS im-
age, a type of “volumetric density” image (Davatzikos, 1998; Davatzikos et
al., 2001; Goldszal et al., 1998; Shen et al., 2003) that has been validated
for voxel-based analysis (Davatzikos et al., 2001) and applied both to AD
e.g. (Davatzikos et al., 2010; Misra et al., 2009; Wang et al., 2010) and other
studies e.g. (Fan et al., 2007)7. For each of the three processed RAVENS tis-
sue maps (gray matter (GM), white matter (WM), and ventricle), to reduce
4 Data used in the preparation of this article were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). The ADNI was launched
in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical
Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private
pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-
private partnership. The primary goal of ADNI has been to test whether serial mag-
netic resonance imaging (MRI), positron emission tomography (PET), other biological
markers, and clinical and neuropsychological assessment can be combined to measure the
progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). De-
termination of sensitive and specific markers of very early AD progression is intended to
aid researchers and clinicians to develop new treatments and monitor their effectiveness,
as well as lessen the time and cost of clinical trials.
5ADNI image correction steps include Gradwarp, N3, and scaling for gradient drift –
see www.loni.ucla.edu/ADNI/Data/ADNI Data.shtml.
6We describe our processing of RAVENS images in Appendix A.
7Of particular interest, (Davatzikos et al., 2001) supported that voxel-based SPM statis-
tical analysis, which we perform herein for comparison with our methods, can be performed
on RAVENS images.
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complexity for subsequent processing, we obtained a subsample by succes-
sively skipping five voxels along each of the three dimensions, and took as
feature set the union of the three subsampled maps. We will also report
results for the case of skipping only two voxels, rather than five.
Since high-dimensional nonlinear registration (warping) of all individuals
to a common atlas (via HAMMER (Shen et al., 2002)) is applied in pro-
ducing our features, they capture both volumetric and morphometric brain
characteristics, which is important since individuals with AD/MCI typically
exhibit brain atrophy (affecting both volume and shape).
2.3. Classification and feature selection for high-dimensional images
A challenge in building classifiers for medical images is the relative paucity
of available training samples, compared to the huge dimensionality of the
voxel space and, thus, to the number of parameters in the classifier model –
in general, the number of parameters may grow at least linearly with dimen-
sionality. In the case of 3D images, this could imply even millions of param-
eter values (e.g. one per voxel) need to be determined, based on a training
set of only a few hundred patient examples. In such cases, classifier over-
fitting is likely, which can degrade generalization (test set) accuracy. Here
we will apply a linear discriminant function (LDF) classifier with a built-in
mechanism to avoid overfitting and with design complexity that scales well
with increasing dimensionality - the support vector machine (SVM) (Vap-
nik, 1998). The choice of LDF achieving perfect separation (no classification
errors) for a given two-class training set is not unique. The SVM, however,
is the unique separating LDF that maximizes the margin, i.e. the minimum
distance to the classifier decision boundary, over all training samples. In this
sense, the SVM maximizes separation of the two classes. For an SVM, unlike
a standard LDF, the number of model parameters is bounded by the number
of training samples, rather than being controlled by the feature dimension-
ality. Since the number of samples is the much smaller number for medical
image domains, in this way the SVM greatly mitigates overfitting. SVMs
have achieved excellent classification accuracy for numerous scientific and
engineering domains, including medical image analysis, (Aksu et al., 2010;
Davatzikos et al., 2010; Guyon et al., 2002).
Even though SVMs are effective at mitigating overfitting, generalization
accuracy may still be improved in some cases by removing features that
contribute little discrimination power. Moreover, even if generalization ac-
curacy monotonically improves with increasing feature dimensionality, high
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complexity (both computation and memory storage) of both classifier design
and class decisionmaking may outweigh small gains in accuracy achieved by
using a huge number of features. Most importantly here, it is often useful
to identify the critical subset of features necessary for achieving accurate
classification – these “markers” may shed light on the underlying disease
mechanism. In our case, this will help to identify prognostic brain regions,
associated with MCI conversion.
Unfortunately, there is a huge number of possible feature subsets, with
exhaustive subset evaluation practically prohibited even for modest number
of features, M , let alone M ∼ 106. Practical feature selection techniques are
thus heuristic, with a large range of tradeoffs between accuracy and complex-
ity (Guyon et al., 2003). “Front-end” (or “filtering”) methods select features
prior to classifier training, based on evaluation of discrimination power for
individual features or small feature groups. “Wrapper” methods are gen-
erally more reliable, interspersing sequential feature selection and classifier
design steps, with features sequentially selected to maximize the current sub-
set’s joint discrimination power. There are also embedded feature selection
methods, e.g. for SVMs, use of `1-regularization within the SVM design opti-
mization (Fung et al., 2004), in order to find “sparse” weight vector solutions,
which effectively eliminate many features. For wrappers, there is greedy for-
ward selection, with “informative” features added, backward elimination,
which starts from the full set and removes features, and more complex bidi-
rectional searches. In our work, due to the high feature dimension, we focus
on two backward elimination wrappers that afford practical complexity: i)
the widely used recursive feature elimination algorithm (RFE) (Guyon et al.,
2002), where at each step one removes the feature with least weight magni-
tude in the SVM solution. RFE has been applied before to AD (Davatzikos
et al., 2010; Misra et al., 2009; Wang et al., 2010); ii) the recent margin-
based feature elimination (MFE) algorithm (Aksu et al., 2010), which uses
the same objective function (margin) for feature elimination, one consistent
with good generalization, that the SVM uses for classifier training (Vapnik,
1998). MFE was shown in (Aksu et al., 2010) to outperform RFE (Guyon et
al., 2002) and to achieve results comparable to embedded feature selection
for domains with up to 8,000 features (gene microarray classification). Here
we will also find that MFE gives better results than RFE.
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2.4. An MRI-Derived Alternative to CDR-based MCI-to-AD Conversion
In the Introduction, we outlined our two classifier design steps for build-
ing an automatic prognosticator for an individual with MCI. In this sec-
tion, we elaborate on these two steps and give an illustrative example. Our
AD-Control classifier, used in the first step, is discussed in Sec. 2.4.1, and
our second classifier, used to discriminate converter-by-trajectory (CT) and
nonconverter-by-trajectory (NT) classes, is discussed in Sec. 2.4.2.
2.4.1. AD-Control classifier
For the AD training population, we chose individual AD visit images with
a CDR score of at least 1. For the Control training population, on the other
hand, we only chose initial visits, and only those for participants who stayed
at CDR=0 throughout all their visits. Thus, we excluded Controls with
“questionable dementia” (i.e., CDR=0.5) at any visit. By these choices, we
sought to exclude outlier examples or even possibly any mislabeled examples,
recalling that CDR for the majority of both AD and MCI participants is 0.5
throughout all visits.
2.4.2. CT-NT classifier
Fig. 1 gives an illustrative example of the phenotypical score trajecto-
ries for MCI subject described in the Introduction. A positive score is on the
Control side and a negative score is on the AD side – the x-axis represents the
AD-Control SVM’s decision boundary. Score vs. age is plotted, with each line
segment a trajectory obtained by linearly fitting an individual’s phenotype
scores (and linearly extrapolating if there are missing visits). Nonconverters-
by-CDR (N-CDR) and converters-by-CDR (C-CDR) are illustrated in (a)
and (b), respectively. Green and black subjects are those whose fitted tra-
jectory stayed on the Control side and AD side, respectively, whereas gray
lines are subjects who crossed to the AD side. Thus, by our conversion-by-
trajectory definition, the green group is the nonconverters-by-trajectory, and
the black and gray groups together are the converters-by-trajectory. Subject
counts for these groups are given in the figure legends. The outlier sub-
jects are shown in orange – there are five, making up less than 2% of the
MCI cohort. Notice, intriguingly, from the left figure that more than one
third of all (non-orange) MCI patients (106 of 298) are converters by tra-
jectory and yet nonconverters according to CDR – i.e., there is a very large
percentage of patients for which the two converter definitions disagree, with
the neuroimage-based definition indicating disease state changes that are not
12
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Figure 1: AD-Control SVM score trajectories for MCI subjects. (a) Nonconverters-by-
CDR. (b) Converters-by-CDR.
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predicted using the clinical, CDR-based definition. Likewise, an additional
3% of all MCI subjects (11 of 298) “defy” their by-CDR converter label in
that they do not reach the AD side of the decision boundary.
Based on these trajectories, i.e. whether or not the AD side is visited, we
derive the ground-truth ‘CT’ and ‘NT’ labels for all MCI subjects. We then
build a CT-NT classifier using as input only the image scans at initial visit.8
3. Results and Discussion
3.1. Introductory overview
In this section we will perform 1) classification experiments to evaluate
conversion-by-trajectory and conversion-by-CDR with respect to desidera-
tum 2; 2) additional experiments to compare the two definitions with re-
spect to desideratum 3; and lastly, 3) experiments to identify prognostic
brain “biomarker” regions.
It is important to mitigate the potential confounding effect of the subject’s
age. In our classification experiments, we mitigated in two ways:
1) For every classifier training, each training sample in one class was
uniquely paired via “age-matching” with a training sample in the other class
(with age separation at most one year).
2) For every linear-kernel SVM classifier, we separately adjusted each
feature for age prior to classification using linear fitting. We subtracted
the extrapolated line (computed only using “control” samples9) from the
feature’s value, for all (training and test) samples. As an aside, we note
that, given the subsequent linear SVM operation, the representation power
of this linear fitting step is essentially equivalent to simply treating age as
an additional feature input to the linear SVM classifier.
Finally, prior to building classifiers, we normalized feature values to the
[0,1] range, which is suitable for the LIBSVM software (Chang et al., 2001)
we used for training SVMs.
8For a small percentage of the MCI subjects, we did not obtain the patient’s first visit.
However, we did ensure that the visit we took as the “initial visit” had a CDR of 0.5.
9For the AD-Control classifier, these are the samples in the Control class. For the
CT-NT classifier we computed the line using only the NT samples.
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(a) By-CDR. (b) By-trajectory. (c) Overlap.
Figure 2: A population of 298 MCI subjects in ADNI (approximately 75% of the MCI population size of 400 targeted by ADNI) is shown here, broken up according
to the two criteria discussed in Sec. 3.2.1: (a) by-CDR criterion, (b) by-trajectory criterion; with overlap shown in (c).
same sets);11 ii) we can make the training sets of the two clas-
sifiers identical rather than merely same-sized, as well as make
the test sets identical. This latter approach, though, will have
some bias because, in selecting samples for the by-trajectory
classifier, we will have to make use of knowledge of the sam-
ples’ conversion-by-CDR status (and vice versa for the by-CDR
classifier). The first approach, on the other hand, clearly does
not have this bias. As both approaches are valid ways of dealing
with by-CDR data limitations, we will compare generalization
accuracies of by-CDR and by-trajectory classifiers under both
these data selection schemes, referring to these approaches as
“random” and “identical” in the sequel.
Our training/test set selection procedure for the “identical ap-
proach” is as follows. For the C-CDR-CT group (Fig. 2(c)),
randomly select 80% of the group (the yellow striped group of
size 30 in Fig. 3(a)) such that a corresponding group within N-
CDR (white portion in Fig. 2(a)) can be found that is both NT
and satisfies age-matching. This corresponding group is illus-
trated in Fig. 3(a) as the white striped group (of size 30), placed
opposite from the yellow striped area it is paired (matched)
with. Likewise for the C-CDR-NT group (Fig. 2(c)), randomly
select 80% of the group (the yellow striped group of size 9 in
Fig. 3(a)) such that a corresponding group within N-CDR can
be found that is both CT and satisfies age-matching. This cor-
responding group is illustrated in Fig. 3(a) as the white striped
group (of size 9). Notice by comparing this figure to Fig. 2(c)
that the two white striped areas are separated by the CT-NT
border. We take the training set – shared by the by-CDR and
by-trajectory classifiers – to be precisely the union of these four
striped areas.12 Subsequently, we take the test set – shared by
the two classifiers – to be the subjects who are neither in 1) the
training set (striped areas) nor in 2) the special set of subjects
shown in solid gray in Fig. 3(a) (also shown identically in Fig.
11Note that this means that the training sets for the converter and noncon-
verter classes of the conversion-by-CDR classifier are randomly selected from
the yellow and white regions in Fig. 2(a), respectively, with no consideration
of trajectory-based (i.e. red/white) labeling illustrated in Fig. 2(b).
12For the by-CDR classifier, the class membership of any of these four sub-
sets of the training set is illustrated by the color being yellow or white in Fig.
3(a). Likewise, for the by-trajectory classifier, class membership is illustrated
by red or white color in Fig. 3(b).
3(b)).13 That is, the test set is the tiled areas in Fig. 3(a) (or,
identically, in Fig. 3(b)).
Note above that some random selection is being employed in
choosing the training/test sets even in the “identical approach”
(whereas, in the “random approach” the selection is completely
random). Thus, for both approaches, the accuracy of perfor-
mance comparison will benefit from averaging accuracy results
over multiple training/test split “trials”. Results averaged across
10 trials are given in Fig. 3(c) for a linear-kernel SVM14; µ±σ
notation is used to indicate the mean µ and standard deviation
σ of quantities across the trials.15 Note that by-trajectory’s gen-
eralization performance is as high as 0.83, whereas by-CDR’s
generalization performance is very poor – as poor as random
guessing (see 0.5 and 0.56 table values) – due mainly to poor
performance on nonconverters-by-CDR. Fig. 3(d) and Fig. 3(e)
show by-trajectory and by-CDR results, respectively, for one of
the 10 trials (for the “random approach”), with each bar indi-
cating distance to the classification boundary16 for an MCI sub-
ject in a test population of size 88 and nonconverters/converters
shown in left/right figures, respectively. Among the 88 subjects,
by-trajectory correctly classified 79 whereas by-CDR correctly
classified only 40.
In a separate experiment, we evaluated using one of 27 sub-
samples (rather than one of 216 subsamples), i.e. essentially
a 10-fold increase in the number of (voxel-based) features, and
found that the by-trajectory generalization accuracy rose to 0.91
in the “random” case. We then tried building 27 separate by-
converter classifiers, one for every 1/27th subsample (thus ef-
fectively using the whole 3D image), with majority-based vot-
ing used to combine the 27 decisions. This ensemble scheme
again achieved 0.91 accuracy, i.e. there was no further accuracy
13We exclude this “special set” (in gray) from the test set so that all our
experiments under the “identical approach” can have a shared, fixed test set
(for fair comparison with each other), including, crucially, an experiment that
will include this “special set” of samples in the training set.
14For generating all classification results herein, including those in Fig. 3(c),
we used SVM classifiers that were built by employing the common approach of
bootstrap-based validation for selecting the classifier’s (trial’s) hyperparameter
values (Aksu et al., 2010).
15µ and σ of integer quantities (e.g. sample counts) are shown rounded up.
16Positive/negative distance means nonconverter/converter side of the bound-
ary, respectively.
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(a) By-CDR. (b) By-trajectory. (c) Overlap.
Figure 2: A population of 298 MCI subjects in ADNI is shown here, broken up according to
the two criteria discussed in Sec. 3.2.1: (a) by-CDR criterion, (b) by-trajectory criterion;
with overlap shown in (c).
3.2. Experiments with voxel-based features
The test set (generalization) accuracy of the voxel-based AD-Control clas-
sifier, built using 70 training samples per class, was 0.89 (86 of 88 Controls,
and 16 of 27 AD subjects, were correctly classified.) This classifier, with high
s ecificity for Controls, was then applied to a population of MCI subjects to
de ermine t e CT n NT subgroups.
3.2.1. Classification experiments for the MCI pop lati n
Fig. 2(a) shows the sizes of the converter-by-CDR (C-CDR) and nonconverter-
by-CDR (N-CDR) groups within the ADNI MCI cohort for a typical exper-
iment in our work. Fig. 2(b) shows the same population broken up as
converters-by-trajectory (CT) and nonconverters-by-trajectory (NT). Super-
imposing the two charts, Fig. 2(c) illustrates their overlap, where converters
by both definitions are accordingly indicated by orange. Since converters-
by-CDR are relatively scarce, we sed a l rge majority of them (80%, i.e. 39
indiv duals among the 48) for the by-CDR cl ssifier’s trai ing set, with the
rest (20%) put in o the test se . We reiterate that a eneral disadvantage of
the by-CDR ap roach is its scarcity of converter examples – by contrast, a
more balanced number of examples is available for by-trajectory training (at
least 100, rather than 39, training samples per class, as in Fig. 2(b)). Note
also that if we were to use a “probable AD”, rather than a by-CDR converter
definition, there would be even fewer converter examples.
A fair performance comparison between by-trajectory and by-CDR clas-
sification requires: 1) using the same per-class training set size (i.e. 39) for
15
both by-CDR and by-trajectory training, and 2) making the test set sizes
the same for both classifiers. There are several different ways in which the
data can be partitioned into training and test sets, consistent with these two
conditions: i) we can perform simple random selection on a class-by-class ba-
sis, ensuring only that the two classifiers are given the same training/test set
sizes (but not the same sets);10 ii) we can make the training sets of the two
classifiers identical rather than merely same-sized, as well as make the test
sets identical. This latter approach, though, will have some bias because, in
selecting samples for the by-trajectory classifier, we will have to make use of
knowledge of the samples’ conversion-by-CDR status (and vice versa for the
by-CDR classifier). The first approach, on the other hand, clearly does not
have this bias. As both approaches are valid ways of dealing with by-CDR
data limitations, we will compare generalization accuracies of by-CDR and
by-trajectory classifiers under both these data selection schemes, referring to
these approaches as “random” and “identical” in the sequel.
Our training/test set selection procedure for the “identical approach”
is as follows. For the C-CDR-CT group (Fig. 2(c)), randomly select 80%
of the group (the yellow striped group of size 30 in Fig. 3(a)) such that
a corresponding group within N-CDR (white portion in Fig. 2(a)) can be
found that is both NT and satisfies age-matching. This corresponding group
is illustrated in Fig. 3(a) as the white striped group (of size 30), placed
opposite from the yellow striped area it is paired (matched) with. Likewise
for the C-CDR-NT group (Fig. 2(c)), randomly select 80% of the group (the
yellow striped group of size 9 in Fig. 3(a)) such that a corresponding group
within N-CDR can be found that is both CT and satisfies age-matching. This
corresponding group is illustrated in Fig. 3(a) as the white striped group (of
size 9). Notice by comparing this figure to Fig. 2(c) that the two white
striped areas are separated by the CT-NT border. We take the training set
– shared by the by-CDR and by-trajectory classifiers – to be precisely the
union of these four striped areas.11 Subsequently, we take the test set –
10Note that this means that the training sets for the converter and nonconverter classes
of the conversion-by-CDR classifier are randomly selected from the yellow and white re-
gions in Fig. 2(a), respectively, with no consideration of trajectory-based (i.e. red/white)
labeling illustrated in Fig. 2(b).
11For the by-CDR classifier, the class membership of any of these four subsets of the
training set is illustrated by the color being yellow or white in Fig. 3(a). Likewise, for the
by-trajectory classifier, class membership is illustrated by red or white color in Fig. 3(b).
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shared by the two classifiers – to be the subjects who are neither in 1) the
training set (striped areas) nor in 2) the special set of subjects shown in solid
gray in Fig. 3(a) (also shown identically in Fig. 3(b)).12 That is, the test set
is the tiled areas in Fig. 3(a) (or, identically, in Fig. 3(b)).
Note above that some random selection is being employed in choosing the
training/test sets even in the “identical approach” (whereas, in the “random
approach” the selection is completely random). Thus, for both approaches,
the accuracy of performance comparison will benefit from averaging accuracy
results over multiple training/test split “trials”. Results averaged across 10
trials are given in Fig. 3(c) for a linear-kernel SVM13; µ± σ notation is used
to indicate the mean µ and standard deviation σ of quantities across the
trials.14 Note that by-trajectory’s generalization performance is as high as
0.83, whereas by-CDR’s generalization performance is very poor – as poor
as random guessing (see 0.5 and 0.56 table values) – due mainly to poor
performance on nonconverters-by-CDR. Fig. 3(d) and Fig. 3(e) show by-
trajectory and by-CDR results, respectively, for one of the 10 trials (for the
“random approach”), with each bar indicating distance to the classification
boundary15 for an MCI subject in a test population of size 88 and non-
converters/converters shown in left/right figures, respectively. Among the
88 subjects, by-trajectory correctly classified 79 whereas by-CDR correctly
classified only 40.
Recently, similarly poor by-CDR classification performance was also re-
ported in (Davatzikos et al., 2010), where it was found that the majority
of (by-CDR) nonconverters “had sharply positive SPARE-AD scores indi-
cating significant atrophy similar to AD patients”. Since the SPARE-AD
score is produced by a classifier that was trained to discriminate Control and
AD patients (Fan et al., 2007, 2008), this comment and associated results
are consistent both with our conjecture in the Introduction and our above
12We exclude this “special set” (in gray) from the test set so that all our experiments
under the “identical approach” can have a shared, fixed test set (for fair comparison with
each other), including, crucially, an experiment that will include this “special set” of
samples in the training set.
13For generating all classification results herein, including those in Fig. 3(c), we used
SVM classifiers that were built by employing the common approach of bootstrap-based
validation for selecting the classifier’s (trial’s) hyperparameter values (Aksu et al., 2010).
14µ and σ of integer quantities (e.g. sample counts) are shown rounded up.
15Positive/negative distance means nonconverter/converter side of the boundary, re-
spectively.
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histogram results, which suggest that there may be a significant number of
patients undergoing physiological brain changes consistent with conversion,
yet without clinical manifestation.
The results above indicate that the conversion-by-CDR definition’s two
classes are not well-discriminated, and thus, clinical usefulness of this def-
inition for our prognostic Aim is expected to be poor. The much greater
generalization accuracy of the by-trajectory definition (coupled with its in-
herent plausibility as a conversion definition) indicates its greater utility.
Increasing the By-Trajectory Image-Based Feature Resolution:
In a separate experiment, we evaluated using one of 27 subsamples (rather
than one of 216 subsamples), i.e. essentially a 10-fold increase in the number
of (voxel-based) features, and found that the by-trajectory generalization ac-
curacy rose to 0.91 in the “random” case. We then tried building 27 separate
by-converter classifiers, one for every 1/27th subsample (thus effectively us-
ing the whole 3D image), with majority-based voting used to combine the
27 decisions. This ensemble scheme again achieved 0.91 accuracy, i.e. there
was no further accuracy benefit beyond that from an ≈ 10-fold increase in
the number of voxel features.
Increasing the By-Trajectory Training Set Size
Note that the converter-by-CDR sample scarcity and class-balancing (via
age-matching) in the experiments above had the effect of artificially limiting
the by-trajectory classifier training set size. Next we investigated how much
the generalization accuracy of by-trajectory classification improves when this
limitation is removed. The tiled areas in Figures 4(a) and 3(b) are identical,
illustrating that in this new experiment (Fig. 4(a)) we used the same test set
as previously, for fairness of comparison. However, as indicated by differences
in the total striped area between these two charts, we now make the training
set much larger than previously. Specifically, for the “identical” case, we used
the previous 10 trials but simply augmented a trial’s training set with the
two large, previously-excluded gray sets16, as these two sets do age-match
each other. The results, averaged across the 10 trials, are given in Fig.
4(b). Notice in this figure the now larger per-class training size (on average
≈ 100 rather than 39), and that the random approach uses this size as
well. The by-trajectory results in Fig. 4(b) indicate that accuracy improved
from 0.78 ± 0.02 (Fig. 3(c)) to 0.84 ± 0.02 for the “identical approach”,
16Shown in Fig. 3(b), with size 60. Note that this size can vary from trial to trial.
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(a) Training/test set selection for by-CDR classifi-
cation.
(b) Training/test set selection for by-trajectory clas-
sification.
Sample Classifier Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
Random By-trajectory 46 ± 1 0.81 ± 0.06 45 ± 1 0.84 ± 0.05 0.83 ± 0.05
approach By-CDR 9 ± 1 0.79 ± 0.07 82 ± 2 0.47 ± 0.04 0.50 ± 0.04
Identical By-trajectory 45 ± 1 0.78 ± 0.04 47 ± 2 0.78 ± 0.04 0.78 ± 0.02
approach By-CDR 9 ± 1 0.74 ± 0.11 82 ± 2 0.54 ± 0.04 0.56 ± 0.04
(c) Average test set classification accuracy using all 11, 293 features, 39±1 per-class training
samples.
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Figure 3: Test set accuracy comparison of by-CDR and by-trajectory classification.
9
( ) Training/test set selec-
tion for by-CDR classifica-
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cation.
(b) Training/test set selection for by-trajectory clas-
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(b) Training/test set selec-
tion for by-traject ry clas-
sification.
Sample Classifier Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
Random By-trajectory 46± 1 0.81± 0.06 45± 1 0.84± 0.05 0.83± 0.05
approach By-CDR 9± 1 0.79± 0.07 82± 2 0.47± 0.04 0.50± 0.04
Identical By-trajectory 45± 1 0.78± 0.04 47± 2 0.78± 0.04 0.78± 0.02
approach By-CDR 9± 1 0.74± 0.11 82± 2 0.54± 0.04 0.56± 0.04
(c) Av rage test set classification ac uracy using all 11, 293 features, 39±1 per-class
training samples.(a) Training/test set selection for by-CDR classifi-
cation.
(b) Training/test set selection for by-trajectory clas-
sification.
Sample Classifier Test set
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Count Accuracy Count Accuracy accuracy
Random By-trajectory 46 ± 1 0.81 ± 0.06 45 ± 1 0.84 ± 0.05 0.83 ± 0.05
approach By-CDR 9 ± 1 0.79 ± 0.07 82 ± 2 0.47 ± 0.04 0.50 ± 0.04
Identical By-trajectory 45 ± 1 0.78 ± 0.04 47 ± 2 0.78 ± 0.04 0.78 ± 0.02
approach By-CDR 9 ± 1 0.74 ± 0.11 82 ± 2 0.54 ± 0.04 0.56 ± 0.04
(c) Average test set classification accuracy using all 11, 293 features, 39±1 per-class training
samples.
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approach By-CDR 9 ± 1 0.79 ± 0.07 82 ± 2 0.47 ± 0.04 0.50 ± 0.04
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approach By-CDR 9 1 0.74 ± 0.11 82 ± 2 0.54 ± 0.04 0.56 ± 0.04
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(a) Training/test set selection for by-trajectory clas-
sification.
Sample Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
By-trajectory Random 45 ± 1 0.77 ± 0.01 47 ± 2 0.86 ± 0.02 0.82 ± 0.01
Identical 45 ± 1 0.85 ± 0.03 47 ± 2 0.83 ± 0.05 0.84 ± 0.02
(b)
Figure 4: By-trajectory average test set classification accuracy for the larger training set size (98 ± 1 per class) and 11, 293 features.
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Figure 5: For the hippocampus, by-trajectory (red) has larger histogram separation between converter (dashed line) and nonconverter (solid line) groups than by-
CDR (blue). To illustrate this more clearly, also shown is the Gaussian curve for each of these four subject groups (plotted based on group mean (m) and standard
deviation (s) indicated in the figure legend with the same 0.001 scaling as the x-axis).
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(a) Training/test set selection for
by-trajectory classification.
Sample Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
By-trajectory Random 45± 1 0.77± 0.01 47± 2 0.86± 0.02 0.82± 0.01
Identical 45± 1 0.85± 0.03 47± 2 0.83± 0.05 0.84± 0.02
(b)
Figure 4: By-trajectory average test set classification accuracy for the larger training set
size (98± 1 per class) and 11, 293 features.
and modestly worsened for the “random approach” (from 0.83 ± 0.05 to
0.82± 0.01).
Evaluating a Third Conversion Definition
We now consider a third definition of conversion that combines the first
two definitions as follows. Let “converters” consist of individuals who con-
verted either by-trajectory or by-CDR (non-white areas in Fig. 2(c)), with
the “nonconverter” class consisting of the remaining MCI individuals (white
area). The point of view of this new definition, “conversion-by-union”, is to
be more inclusive in defining an MCI subpopulation at risk, which may ben-
efit from early treatment or diagnostic testing. While from that perspective
the new definition is reasonable, the fact that grouping individuals by CDR
has a role in this definition may be its disadvantage, considering that by-CDR
classification was previo sly shown to perform not much better than random
guessing. Results, averaged across the same 10 trials used in Fig. 3, are
given in Table 1 and indicate that conversion-by-union generalizes somewhat
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Sample Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
By-union Identical 48± 1 0.78± 0.05 44± 2 0.75± 0.06 0.77± 0.03
Table 1: Average test set accuracy of by-union classification for 39± 1 per-class training
samples and 11, 293 features.
worse than conversion-by-trajectory.17
3.2.2. Validation on Known AD Conversion Biomarkers
To validate the proposed conversion definitions with respect to desider-
atum 3, we performed correlation tests on the MCI population between the
binary class variable C ∈ {0 = no conversion, 1 = conversion} and known
AD conversion biomarkers consisting of both 1) volume in reported AD-
affected regions (Table 2 in (Schuff et al., 2010)), which we measured for
each individual’s final-visit MRI18 and 2) the clinical MMSE measure. The
stronger the correlation, the more accurately the biomarker is predicted from
the class variable and the greater the separation between the biomarker his-
tograms, conditioned on the two classes.
Before presenting correlation test results, we first illustrate in Fig. 5
the increased separation of the histograms of hippocampus volume for the
converter and nonconverter groups in the by-trajectory case, compared with
by-CDR. Next, we performed comprehensive statistical tests for a number of
suggested AD biomarkers. The R statistical computing package was used to
perform all tests with statistical significance set at the 0.05 level. In Table 2a
17Note that “by-union” is, by definition, an instance of the “identical approach”, as
stated in Table 1. To ensure fairness of comparison with the by-trajectory definition of
conversion, our test sets, and training set sizes, in these two cases were identical. In fact,
we chose the by-union training set to be as similar to by-trajectory’s, in every trial, as
possible. Referring to Fig. 3(b) (which represents a trial example), the by-union training
set was chosen to include 1) the two large striped groups (red and white); 2) the small
“special” gray group (of size seven in this trial example) and its age-matched counterpart
within small white-striped group, and; 3) a subset of the second small “special” gray group
(two of five individuals in this trial example) and its age-matched counterpart within the
small red-striped group.
18As discussed in Appendix A, we measured normalized region volume. Note also that
our regions are defined based on the atlas (Atlas2) we used. The correspondence between
the regions in (Schuff et al., 2010) and our defined regions is given in Appendix B. Finally,
note that a subject’s final visit is not always the sixth visit.
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(a) Training/test set selection for by-trajectory clas-
sification.
Sample Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
By-trajectory Random 45 ± 1 0.77 ± 0.01 47 ± 2 0.86 ± 0.02 0.82 ± 0.01
Identical 45 ± 1 0.85 ± 0.03 47 ± 2 0.83 ± 0.05 0.84 ± 0.02
(b)
Figure 4: By-trajectory average test set classification accuracy for the larger training set size (98 ± 1 per class) and 11, 293 features.
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48 [m=−0.654, s=0.924]
155 [m=0.399, s=0.896]
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Figure 5: For the hippocampus, by-trajectory (red) has larger histogram separation between converter (dashed line) and nonconverter (solid line) groups than by-
CDR (blue). To illustrate this more clearly, also shown is the Gaussian curve for each of these four subject groups (plotted based on group mean (m) and standard
deviation (s) indicated in the figure legend with the same 0.001 scaling as the x-axis).
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Figure 5: For the ippocamp , by-trajectory (r d) ha large histogram eparation be-
tween converter (dashed line) and nonconverter (solid line) groups than by-CDR (blue).
To illustrate this more clearly, also shown is the Gaussian curve for each of these four
subject groups (plotted based on group mean (m) and standard deviation (s) indicated in
the figure legend with the same 0.001 scaling as the x-axis).
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(and Fig. 6), the correlation coefficients for by-trajectory and by-CDR are
shown for each biomarker, along with their associated p-values (Chambers
et al., 1993). Note that for 11 out of 14 brain regions, the correlation with
by-trajectory is greater than the correlation with by-CDR (in bold), with
by-trajectory meeting the significance threshold in 10 of these 11 regions.
Further, for only two of the remaining four biomarkers - posterior cingulate
and the clinical MMSE measure - does the correlation with by-CDR meet the
significance threshold. Most notably, well-established markers for AD such
as the hippocampus, lateral ventricles, and inferior parietal exhibited strong
correlation with the by-trajectory definition.
To further assess statistical significance of the comparison between by-
trajectory and by-CDR correlations, we performed a correlated correlation
test (Meng et al., 1992), the appropriate test given that the same MCI sam-
ple population was used in measuring correlations for both by-CDR and
by-trajectory. This test (Table 2b) reveals that the larger correlation of by-
trajectory is statistically significant at the 0.05 level in nine brain regions (in
bold). By contrast, conversion-by-CDR does not achieve a statistically sig-
nificant advantage for any of the brain regions, nor with respect to MMSE.
To mitigate the confounding effect of age in the AD biomarker measurements,
we linearly adjusted them for age prior to performing the experiments de-
scribed above. We also repeated these experiments without age adjustment.
In this case, the number of regions for which by-trajectory’s correlation ex-
ceeded by-CDR’s rose from 11 to 12 (with the addition of the entorhinal
cortex), and the number of regions for which the larger correlation of by-
trajectory was statistically significant rose from 9 to 10 (with the addition of
the medial orbitofrontal GM).
3.2.3. Identification of prognostic brain “biomarker” regions
In the previous section, we validated conversion definitions using estab-
lished (diagnostic) AD biomarker brain regions (with volumes measured at
final visit). In this section, we will identify key prognostic biomarker brain
regions via supervised feature selection, aiming first to identify the “essen-
tial” subset of voxel features, i.e. the voxels (at initial visit) necessary for
our classifier to well-discriminate the CT and NT classes. The brain regions
(consistent with a registered brain atlas) within which these select voxels
principally reside then identify our prognostic brain biomarker regions. Sim-
ilarly, we will identify diagnostic regions, critical for discriminating between
AD and Control subjects (using our AD-Control classifier). In both cases,
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(a)
By-trajectory By-CDR
Correlation P-value Correlation P-value
Biomarker coefficient coefficient
Entorhinal cortex 0.041 0.486 0.050 0.385
Fusiform gyrus 0.430 8.20E-15 0.152 0.008
Hippocampus 0.530 2.00E-16 0.231 5.67E-05
Inferior parietal GM 0.513 2.00E-16 0.097 0.094
Lateral orbitofrontal GM 0.077 0.185 0.078 0.178
Lateral ventricles 0.586 2.00E-16 0.211 0.000246
Medial orbitofrontal GM 0.239 3.01E-05 0.101 0.081
Parahippocampal gyrus 0.095 0.102 0.060 0.307
Posterior cingulate 0.001 0.981 0.144 0.013
Precentral GM 0.173 0.003 0.088 0.128
Superior frontal GM 0.331 4.50E-09 0.094 0.104
Superior temporal GM 0.478 2.00E-16 0.161 0.005
Total GM 0.491 2.00E-16 0.246 1.70E-05
Total WM 0.170 0.003 0.041 0.477
MMSE 0.356 2.57E-10 0.453 2.00E-16
(b)
P-value
0.889
2.17E-06
2.42E-10
0.985
1.34E-09
0.048
0.616
0.045
0.230
0.001
3.10E-05
0.0001
0.069
1.33E-06
0.118
Table 2: Correlation coefficients and associated p-values: (a) Correlation test results; (b)
Correlated correlation test results for each of the regions in (a). Statistically significant
results are shown in bold.
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Figure 6: Comparison of correlation coefficients for by-trajectory and by-CDR.
To further assess statistical significance of the comparison
between by-trajectory and by-CDR correlations, we performed
a correlated correlation test (Meng et al., 1992), the appropri-
ate test given that the same MCI sample population was used
in measuring correlations for both by-CDR and by-trajectory.
This test (Table 2b) reveals that the larger correlation of by-
trajectory is statistically significant at the 0.05 level in nine
brain regions (in bold). By contrast, conversion-by-CDR does
not achieve a statistically significant advantage for any of the
brain regions, nor with respect to MMSE. To mitigate the con-
founding effect of age in the AD biomarker measurements, we
linearly adjusted them for age prior to performing the exper-
iments described above. We also repeated these experiments
without age adjustment. In this case, the number of regions
for which by-trajectory’s correlation exceeded by-CDR’s rose
from 11 to 12 (with the addition of the entorhinal cortex), and
the number of regions for which the larger correlation of by-
trajectory was statistically significant rose from 9 to 10 (with
the addition of the medial orbitofrontal GM).
3.2.3. Identification of key prognostic brain “biomarker” re-
gions
In the previous section, we validated conversion defini-
tions using established (diagnostic) AD biomarker brain regions
(with volumes measured at final visit). In this section, we will
identify key prognostic biomarker brain regions via supervised
feature selection, aiming first to identify the “essential” subset
of voxel features, i.e. the voxels (at initial visit) necessary for
our classifier to well-discriminate the CT and NT classes. The
brain regions (consistent with a registered brain atlas) within
which these select voxels principally reside then identify our
prognostic brain biomarker regions. Similarly, we will iden-
tify diagnostic regions, essential for discriminating between
(a)
By-trajectory By-CDR
Correlation P-value Correlation P-value
Biomarker coefficient coefficient
Entorhinal cortex 0.041 0.486 0.050 0.385
Fusiform gyrus 0.430 8.20E-15 0.152 0.008
Hippocampus 0.530 2.00E-16 0.231 5.67E-05
Inferior parietal GM 0.513 2.00E-16 0.097 0.094
Lateral orbitofrontal GM 0.077 0.185 0.078 0.178
Lateral ventricles 0.586 2.00E-16 0.211 0.000246
Medial orbitofrontal GM 0.239 3.01E-05 0.101 0.081
Parahippocampal gyrus 0.095 0.102 0.060 0.307
Posterior cingulate 0.001 0.981 0.144 0.013
Precentral GM 0.173 0.003 0.088 0.128
Superior frontal GM 0.331 4.50E-09 0.094 0.104
Superior temporal GM 0.478 2.00E-16 0.161 0.005
Total GM 0.491 2.00E-16 0.246 1.70E-05
Total WM 0.170 0.003 0.041 0.477
MMSE 0.356 2.57E-10 0.453 2.00E-16
(b)
P-value
0.889
2.17E-06
2.42E-10
0.985
1.34E-09
0.048
0.616
0.045
0.230
0.001
3.10E-05
0.0001
0.069
1.33E-06
0.118
Table 2: Correlation coefficients and associated p-values.
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Figure 6: Comparison of correlation coefficients for by-trajectory and by-CDR.
AD-Control cl sifier only int rsection CT-NT classifier only
Amygdala left Hippocampal formation* left Superior temporal gyrus* left
Cingulate region right Hippocampal formation* right Middle temporal gyrus left
Entorhinal cortex right Entorhinal cortex* left Precuneus right
Inferior occipital gyrus right Inferior temporal gyrus right Lateral front-orbital gyrus* right
Medial occipitotemporal gyrus left Lateral occipit temporal gyrus* right Insula right
Parahippocampal gyrus left P rahippocampal gyrus* right Supramarginal gyrus* left
Temporal lobe WM right Perirhinal cortex left Temporal lobe WM left
Temporal pole right Perirhinal cortex right Temporal pole left
Middle temporal gyrus right edial front-orbital gyrus* left
Uncus le t
Table 3: Brain regions identified as biomarkers using voxel-based features and MFE.
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the accuracy of the selected brain region biomarkers rests heavily on the ac-
curacy of the supervised feature selection algorithm we employ. In Figures
7(a) and 7(b), we compare MFE and RFE feature elimination (i.e. feature
selection via feature elimination) for both Control-AD classification and for
CT-NT classification (for one representative, example trial). The curves show
test set accuracy as a function of the number of retained features (which is
reduced going from right to left). Note that the “MFE/MFE-slack” hybrid
method (Aksu et al., 2010)) outperforms RFE for both brain classification
tasks, achieving lower test set error rates, and with much fewer retained fea-
tures. The circle, determined without use of the test set based on the rule in
(Aksu et al., 2010), marks the point at which we stopped eliminating features
by MFE, thus determining the (trial’s) retained voxel set. This MFE-RFE
comparison (and the previous comparison in (Aksu et al., 2010)) supports
our use of MFE to determine brain biomarkers.
To relate the retained voxel set to anatomic regions in the brain, we
overlaid the retained voxel set onto a registered atlas space. For CT-NT
classification, to improve robustness, the final voxel set was formed from
the union of the retained voxel sets from each of ten feature elimination
trials (each using a different, randomly selected training sample subset). For
AD-Control classification, the final voxel set came from a single trial (the
only trial, from which the 10 CT-NT trials stemmed). For each of these
two cases, overlaying the final voxel set onto the co-registered atlas (Atlas2,
defined in Appendix A) yielded between 70-80 anatomic regions. For data
interpretation purposes, we then identified a subset of (biomarker) regions
using the following procedure. First, for each brain region, we measured the
percentage of the region’s voxels that are retained, sorted these percentages,
and then plotted them. As shown in Fig. 8(a), the resulting curve for the
AD-Control case has a distinct knee, which we thus used as a threshold
(0.125) to select the final, retained (diagnostic) regions for AD-Control. We
used the same threshold for the CT-NT curve, shown in Fig. 8(b). This
choice of threshold yields a reasonable number of regions – 19 for the CT-NT
(prognostic) case and 21 for the AD-Control (diagnostic) case.
The resulting sets of identified prognostic and diagnostic biomarkers are
given in Table 3, along with their intersection. The diagnostic markers in the
table include the majority of the known brain regions in the medial tempo-
ral lobe involved in AD pathology. For example, hippocampus atrophy and
lateral ventricle enlargement, particularly in its anterior aspects of the tem-
poral horn, are considered the most prominent diagnostic markers for AD.
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Entorhinal cortical regions, including the perirhinal cortex, are presumably
the earliest sites of degeneration (Braak et al., 1997). Thus, independent
identification by our AD-control classifier of known AD diagnostic biomark-
ers establishes a reasonable basis for applying the same approach to identify
prognostic biomarkers. The brain regions listed as CT-NT prognostic mark-
ers include most known AD diagnostic markers (including 8 of the 12 regions
from (Schuff et al., 2010) (marked by *), 4 of which are also diagnostic mark-
ers), indicating that some AD-linked pathological changes in these brain re-
gions already occurred and remained active in a subset of MCI subjects who
likely progress to AD rapidly. Conversely, the brain areas appearing only on
the prognostic marker list are likely the most active areas of degeneration
during this stage of progression to dementia. These structures tend to be
the brain regions further away from the entorhinal cortex onto the parietal
(Supramarginal gyrus, Precuneus) and temporal cortex (Superior temporal
gyrus and Middle temporal gyrus) regions. All the brain structures listed
in the table are known to be involved in AD (Braak et al., 1997; Chan et
al. , 2003; Frisoni et al., 2009). Thus, the markers in Table 3 suggest an
interesting anatomic pattern of trajectory for MCI conversion to AD which
conforms with the Brak and Brak hypothesis and previous imaging findings
(Chan et al. , 2003; Frisoni et al., 2009). Moreover, the CT-NT regions
uniquely found by our MFE-based procedure in Table 3 may be viewed as
“putative” prognostic markers, and may warrant further investigation.
Finally, we note that we have used a particular criterion (percentage of a
region’s voxels that are retained) to identify biomarker regions, starting from
MFE-retained voxels. While our identified regions are plausible, it is possible
that other (equally reasonable) criteria may produce different biomarker re-
gion results. Thus, the biomarkers we identify should be viewed as anecdotal,
identifying regions that figure prominently in our classifier’s decisionmaking
and also potentially assisting researchers in forming hypotheses about MCI-
to-AD disease progression. However, we do not view the identified regions
as definitive.
3.2.4. Comparison with an SPM-based biomarker identification approach
In the previous section, we used MFE to identify voxels as biomarkers
for the CT and NT classes. Here, using the same CT-NT training and
test populations, we will alternatively identify voxel-based biomarkers us-
ing statistical testing with SPM5 (see: (SPM website)). Subsequently we
will present a classifier generalization accuracy comparison (where accuracy
27
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Figure 7: Test set misclassification rate during the course of feature elimination, for (a)
the AD-Control classifier and (b) the CT-NT classifier.
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Figure 7: [ABOVE ARE NOT THE ACTUAL IMAGES] Image display of brain regions identified as biomarkers using voxel-based features and MFE.
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Figure 8: Test set misclassification rate during the course of feature elimination, for (a) the AD-Control classifier and (b) the CT-NT classifier.
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Figure 9: Sorted retained voxel percentages for initial regions (a) AD-Control; b) CT-NT, used to select final regions (Sec. 3.2.3).
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Figure 9: Sorted retained voxel percentages for initial regions (a) AD-Control; b) CT-NT, used to select final regions (Sec. 3.2.3).
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(b)
Figure 8: Sorted retained voxel percentages for initial regions (a) AD-Control; b) CT-NT,
used to select final regions (Sec. 3.2.3).
28
is again measured on the previous section’s CT-NT (test) population) for
these two biomarker detection methods. We determined SPM biomarkers
as follows. The CT-NT training set population, being age-matched, is read-
ily suitable for a paired t-test, an appropriate statistical test for determining
SPM-identified biomarkers, i.e. voxels that discriminate between the CT and
NT groups. In contrast with MFE’s use of only one (out of 216) RAVENS
subsamples (taken jointly from the GM, WM, ventricle maps), we performed
t-tests on whole RAVENS maps (without subsampling), which makes the
SPM-MFE comparison favorably biased towards SPM. More specifically our
steps were as follows. First, for the GM and WM maps separately, we found
using SPM that a large portion of each of these two tissues was statistically
significant at the 0.05 level when correction for multiple comparisons was
not applied. Next, we used SPM’s FDR-based correction for multiple com-
parisons – based on an SPM FDR cluster size of 5 voxels we found that the
spatial extent of the statistically significant regions, at each of the levels 0.05,
0.01, and 0.005, was approximately a subset of the above-mentioned spatial
support found in the uncorrected case. Given that the number of significant
voxels in any of these SPM experiments is, again due to no subsampling,
much larger than the 11,293 voxels started from in the MFE case, we sim-
ply 1) chose as our SPM result the result for 0.01 (FDR-corrected), 2) took
from among those significant voxels the most significant 11,434 voxels in or-
der to be able to compare MFE and SPM for ≈ the same number of voxels
(biomarkers). To obtain the generalization accuracy for this SPM-identified
biomarker voxel set, using the same training/test set as in the MFE experi-
ment, we trained an SVM classifier and measured its generalization accuracy,
which was found to be 0.76. This accuracy is somewhat lower than the 0.8
accuracy of the previous section’s CT-NT SVM classifier. Recalling that this
comparison is actually favorably biased towards SPM, and further noticing
the fact that MFE was able to maintain the 0.8 accuracy all the way down to
2000 features (cf. Fig. 7(b)), this experimental comparison provides another
validation (beyond the comparison with RFE given earlier) for MFE-based
feature/biomarker selection, applied to brain images.
4. Conclusions
We have presented an automated prognosticator of MCI-to-AD conver-
sion based on brain morphometry derived from high resolution ADNI MR
images. The primary novel contributions of our work are: i) casting MCI
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prognostication as a novel machine learning problem lying somewhere be-
tween supervised and unsupervised learning; ii) our proposal of a conversion
definition which, unlike previous methods, exploits both rich phenotypical
information in neuroimages and AD and control examples; iii) correlation
testing and classifier accuracy evaluations to validate candidate conversion
definitions; iv) prognostic biomarker discovery based on our conversion defi-
nition. We demonstrated that our method achieved both better generaliza-
tion accuracy and stronger, statistically significant, correlations with known
brain region biomarkers than a predictor based on the clinical CDR score,
the approach used in several past works. The brain structures identified
as AD-control diagnostic markers and MCI conversion prognostic markers
well conform with known brain atrophic patterns and progression trajecto-
ries occurring in AD-afflicted brains. While the noisy nature of cognitive
assessments, including MMSE, has been acknowledged in past works, in fu-
ture we may extend our methodology to consider cognitive assessment data,
both potentially as additional (baseline) input features and as additional or
alternative prediction targets to our “conversion-by-trajectory” labels. We
may also consider alternative ways to adjust for confounding effects of age,
noting that (Schuff et al., 2010) has characterized the nonlinear dependence
of age on brain region volumes. Finally, while we have focused on the MCI
subpopulation here, our system could also potentially be used to detect, as
possible misdiagnoses, subjects diagnosed as “Control” who are classified as
MCI converters by our system.
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Appendix A. Image processing
The input to our processing is a T1-weighted MR image of the head.
First, using rigid-body registration implemented in FSL’s linear image reg-
istration tool FLIRT (Jenkinson et al., 2001), we coarsely aligned this (3d)
image with the MNI/ICBM atlas resampled to 1mm isotropic voxel dimen-
sions (aka Atlas1). We used FSL version 3 (see: (FSL website)). Next,
we removed non-brain anatomy from the aligned head image, using FSL’s
brain extraction tool BET (Smith et al., 2002). We then segmented the
resulting brain-only 3d image into the following five segments required by
HAMMER(Shen et al., 2002)19 : WM, GM, ventricles, (non-ventricle) CSF,
(non-anatomy) background. Next, using as inputs an MNI atlas distributed
with HAMMER (aka Atlas220) and the ADNI participant’s five-segment im-
age, we performed two different HAMMER operations, generating: 1) the
three “volumetric density” Ravens images: GM, WM, ventricles. The union
of these three images (following some preprocessing) forms the set of features
used by our classifier; 2) the 3d region-segmented image, whose region vol-
umes are used for by-trajectory statistical validation in section 3.2.2 and for
region biomarker identification in section 3.2.3.21
19We used a 2006 version of HAMMER, downloaded on November 8, 2006.
20Since the region-segmented version of the atlas distributed with HAMMER had much
better segmentation quality than the five-segment version, as a pre-processing step we
used the former to create a replacement for the latter (by simply taking the union of all
the regions). The resulting five-segment atlas is dubbed ‘Atlas2’.
21We measured normalized region volumes. We normalized by dividing by the sum of all
(98) region volumes. This sum is essentially intracranial volume minus cerebellum volume,
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Each of these two HAMMER operations performs a different type of atlas-
based nonlinear registration – the one that generates the RAVENS tissue
maps performs less aggressive warping between the five-segment image and
the atlas in order both to combat noise inherent in the registration process
and to preserve volume on a tissue-by-tissue basis (so as to properly detect
and encode brain atrophy). Consequently, there is considerable individual
variability in RAVENS images, which we mitigate in a standard way by
smoothing with a Gaussian filter with an FWHM of 5mm.
The sum of the voxel intensities over the three RAVENS maps is on the
order of 106 and varies across individuals. Thus, prior to smoothing, we
normalized each individual’s Ravens maps, such that each individual has the
same total volume. However, after the normalization and smoothing (aka
“nsRAVENS” images), some areas of poor registration, manifesting as areas
with very low voxel values (including zero), will remain.22 For a population
of nsRAVENS images, these areas are considered to be outlier areas and are
thus removed from each image in the population by thresholding 23. The
resulting images are the features used by our classification system.
Appendix B. Correspondence Between Atlas-defined Regions and
Those Defined in (Schuff et al., 2010)
as our “intracranial region” list includes CSF in addition to brain regions and excludes
the cerebellum.
22A substantial portion of the very low, nonzero voxel intensities are in fact introduced
by the smoothing itself as it calculates each new voxel intensity as a weighted average of
many neighboring voxels (thereby switching some voxels from zero (non-anatomy) to very
low intensity values (anatomy), which essentially slightly grows the anatomy boundaries
outward).
23We calculated the threshold solely using the training population of our AD-Control
classifier, and then applied the thresholding operation on the entire population of AD,
MCI, and Control individuals. In this way, we were careful to exclude test examples from
all phases of classifier training.
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Entorhinal cortex Entorhinal cortex left/right
Fusiform gyrus Lateral occipitotemporal gyrus right/left
Hippocampus Hippocampal formation right/left
Inferior parietal GM Supramarginal gyrus left/right, Angular gyrus right/left
Lateral orbitofrontal GM Lateral front-orbital gyrus right/left
Lateral ventricles Lateral ventricle left/right
Medial orbitofrontal GM Medial front-orbital gyrus right/left
Parahippocampal gyrus Parahippocampal gyrus right/left
Posterior cingulate Cingulate region left/right
Precentral GM Precentral gyrus right/left
Superior frontal GM Superior frontal gyrus left/right
Superior temporal GM Superior temporal gyrus right/left
Table B.4: Correspondence between the regions in (Schuff et al., 2010) (left) (except “Total
GM” and “Total WM”) and our defined regions (right).
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